Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003463177 | SCV004199045 | uncertain significance | Familial meningioma | 2023-08-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003500853 | SCV004280368 | uncertain significance | Neurofibromatosis, type 2 | 2023-09-01 | criteria provided, single submitter | clinical testing | An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals affected with NF2-related conditions. Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. This sequence change replaces lysine, which is basic and polar, with leucine, which is neutral and non-polar, at codon 159 of the NF2 protein (p.Lys159Leu). |